Citations - du Bois Andreas

CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: du Bois Andreas
By: Ilary Ruscito
CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: du Bois Andreas
By: Ilary Ruscito
CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: du Bois Andreas
By: Ilary Ruscito
CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: du Bois Andreas
By: Ilary Ruscito
CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: du Bois Andreas
By: Ilary Ruscito
CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.... Read more
Published on: 2020-06-03
Source: du Bois Andreas
By: Ilary Ruscito
The data presented here is related to the research article entitled "FERTILITY-SPARING SURGERY AND REPRODUCTIVE-OUTCOMES IN PATIENTS WITH BORDERLINE OVARIAN TUMORS" by Plett et al. in Journal of Gynecologic Oncology [1] and is analysed and discussed in detail. 18 Patients with Recurrent Borderline Ovarian Tumors (BOT) were identified and listed... Read more
Published on: 2020-05-13
Source: du Bois Andreas
By: Helmut Plett
  • Other

    Citations

  • Other

    Citations

Translate »